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Refractory cardiogenic shock is an important cause ofdeath in patients after acute myocardial infarction(AMI), therapeutic percutaneous cardiac catheteriza-tion, and cardiac surgery. Of the 1.1 million AMI cases
annually, 7% to 10% have cardiogenic shock, which has a 50% to
60% in-hospital mortality.1 The value of short-term circulatory
support with currently available assist devices is drastically
reduced by thromboembolic, hemorrhagic, and infectious device-
related complications.2 The concept of direct cardiac compression
(DCC), first introduced in 1965,3 is simple and elegant, with sev-
eral advantages over intravascular ventricular assist devices (VAD)
in current use. Use of non-blood contacting DCC systems would
avoid cardiopulmonary bypass and bleeding complications and
would be technically simpler to institute, allowing more wide-
spread use. We evaluated a pneumatic DCC device, the
AbioBooster, designed and fabricated by ABIOMED, Inc
(Danvers, Mass). This device consists of inflatable polyurethane
cylinders wrapped within a silicone-coated polytetrafluoroethyl-
ene fabric. Air pumped into and out of the wrap causes contraction
and dilatation of its circumference (Figure 1). Twelve sheep stud-
ies were performed in nine short-term and three 4-week survival
experiments. The effects of the wrap after induced cardiogenic
shock (esmolol β-blockade with norepinephrine) and ventricular
fibrillation were characterized. To create a reproducible model of
heart failure, we used a continuous infusion of a short-acting
β-blocker, esmolol. An esmolol drip was started at 10 mg/min and
titrated to maintain a descending aortic blood flow at 1.0 L/min or
less. We evaluated the impact of the device on underlying coronary
artery bypass grafts (CABGs) by performing bypasses from the
left internal thoracic artery to the left anterior descending artery (n
= 1) or first diagonal artery (n = 2) and from the innominate artery
to the first obtuse marginal artery (n = 3) using a reversed saphe-
nous vein graft before device application. 
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In the experiments done without CABG, the AbioBooster
device was positioned around the heart and fixed in place with glue
pads and sutures through a left thoracotomy. The device was acti-
vated immediately after implantation and pumping was maintained
for 2 hours. Device-tissue interaction and biocompatibility were
assessed in 3 long-term experiments during which the device was
implanted and left in place for 4 weeks. Shock was induced at
weekly intervals to test the device. At the end of 4 weeks, the heart
was fibrillated and pumping begun in the asynchronous mode. All
animals received humane care in compliance with the “Guide for
the Care and Use of Laboratory Animals” prepared by the Institute
of Laboratory Animal Resources, National Research Council, and
published by the National Academy Press, revised 1996.
The device augmented cardiac output and stroke volume in car-
diogenic shock with no alteration of the mean CABG flow in the
acute setting (Table 1). During ventricular fibrillation, the device
augmented descending aortic blood flow from no detectable flow
to 1.5 ± 0.3 L/min (P = .019). At necropsy in 2 long-term experi-
ments, we observed that the wrap was densely adherent to the
underlying epicardium. Histologic examination revealed a 1.9-mm
mean tissue ingrowth. To prevent this intense reaction, we used a
silicone-coated device. At necropsy, the device was removed easi-
ly with no adhesions detected. No myocardial contusions were
observed, and histologic examination revealed no tissue ingrowth.
Figure 1. The AbioBooster device applied around the heart.
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At necropsy in the short-term CABG experiments, the grafts
showed no evidence of macroscopic injury and had patent anasto-
moses. 
DCC is a simple and effective method of providing circulatory
support but has been underexplored. Intravascular devices have
been successfully used for postcardiotomy, medium-term, and
long-term support of the failing heart.4 However, patients with
acute cardiogenic shock or cardiac arrest have a short time frame
within which cerebral perfusion must be restored to make patient
salvage possible. For this group of patients, intra-aortic balloon
pumping or cardiopulmonary bypass has been used with varying
success. Although the augmentation of cardiac output provided is
often inadequate (10%-15% of baseline), inherent hemorrhagic,
thromboembolic, and ischemic complications are associated with
intra-aortic balloon pumping.5 Cardiopulmonary bypass takes
longer to implement, requires anticoagulation and cannulation, and
is associated with neurologic injury, morbidity, and mortality.6
Although previous studies with DCC showed the ability to provide
adequate circulatory support in the face of acute cardiogenic shock
without blood contact,7,8 these studies failed to assess the device
effects on previous CABG. As many patients may have had previ-
ous revascularization procedures, we evaluated the effect of the
device on graft function. We observed no impairment of CABG
flow during 2 hours of pumping. At necropsy, the anastomotic sites
were patent with no evidence of injury to the conduits. However,
the system was carefully placed in the operating room, and kink-
ing may certainly occur with prolonged use.
In conclusion, our initial results indicate that this device pro-
vides satisfactory circulatory enhancement in acute cardiogenic
shock and is a potentially valuable adjunct in the management of
refractory heart failure.
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TABLE 1. Device function during shock (n = 9)*
Parameter Baseline Shock Augmentation P value
Descending aortic flow (L/m) 3.0 ± 1.0 0.8 ± 0.4 2.9 ± 0.9 .002
Stroke volume (mL) 26.5 ± 7.4 8.5 ± 4.6 25.3 ± 7.7 .004
Mean graft flow (mL/min) (n = 3) 31.3 ± 26.5 28.3 ± 25.6 37.3 ± 36.9 .74
*Descending aortic flow and stroke volume were evaluated in 9 experiments and graft flow in 3 experiments.
